[Thyroid alterations following treatment with pegylated interferon and ribavirin: differences between HIV-coinfected and non-coinfected patients].
Montes-Ramírez
María Luisa
ML
Rodríguez-Zapata
Manuel
M
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D005260:Female; D006679:HIV Seropositivity / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*; D013961:Thyroid Gland / Q000187:drug effects*; D013963:Thyroid Hormones / Q000378:metabolism
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013963:Thyroid Hormones; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b